0
Tape
ATXA$18.42+34.1%BTD granted
IOVX$11.08+12.7%M&A comp
HEPX$6.55-18.3%P3 primary miss
NRVO$27.90+8.4%Enrollment done
CRSP$51.20+4.2%Durability data
RGNX$9.13-6.1%CRL rumor
ATXA$18.42+34.1%BTD granted
IOVX$11.08+12.7%M&A comp
HEPX$6.55-18.3%P3 primary miss
NRVO$27.90+8.4%Enrollment done
CRSP$51.20+4.2%Durability data
RGNX$9.13-6.1%CRL rumor
 Live

The premise

A terminated trial is not a failed drug.

Programs stop for accrual, funding, and strategy far more often than for safety or efficacy. When the hypothesis was never tested, the asset is still live.

Open Work Today's brief

5.8%

cite safety or efficacy

26.9%

stopped on accrual

Four

public sources

Zero

black-box scores

Overnight

What moved

The full brief
Regulatory$ATXA12m

FDA grants Breakthrough Therapy designation to bex-arotene analog in ALS

The agency cited a 41% slowing of functional decline in the Phase 2 CONVERGE readout. A rolling BLA is expected to open in Q3, compressing the review timeline by an estimated four months.

FDA / company release

A case

Tandutinib

Shelved from AML, 2011. Not for safety. Not for efficacy.

Terminated for portfolio prioritization, not safety or efficacy. The open question is glioblastoma.

Open the file
01WorkOpen a discontinued asset. Molecule identity, why it stopped, ResurrectAI hypotheses, a cite-or-unknown memo.02The open databasesOne query across ClinicalTrials.gov, PubMed, and openFDA. No credentials. Nothing invented.03The roomNamed researchers. Specific takes. Follow people, not noise.

Computed from the public registry. Reproduce it. Then decide.